




Mouse Anti-Human IgA₂

Cat. No.	Format	Size
9140-01	Purified (UNLB)	0.5 mg
9140-02	Fluorescein (FITC)	0.5 mg
9140-04	Alkaline Phosphatase (AP)	1.0 mL
9140-05	Horseradish Peroxidase (HRP)	1.0 mL
9140-08	Biotin (BIOT)	0.5 mg
9140-09	R-phycoerythrin (PE)	0.1 mg
9140-30	Alexa Fluor [®] 488 (AF488)	0.1 mg
9140-31	Alexa Fluor [®] 647 (AF647)	0.1 mg



ELISA plate was coated with purified human IgA₁, IgA₂, IgD, IgG, and IgM. Immunoglobulins were detected with serially diluted Mouse Anti-Human IgA₂-HRP (SB Cat. No. 9140-05).

Overview

Clone	A9604D2
Isotype	Mouse IgG _{1κ}
Immunogen	Purified human IgA ₂ m(1) myeloma protein
Specificity	Human IgA ₂ Fc; Mr 170 kDa

Applications

ELISA – Quality tested ¹⁻⁹
 FLISA – Quality tested
 ELISPOT – Reported in literature ¹⁰
 FC – Reported in literature ^{8,16}
 IHC-FS – Reported in literature ^{8,11}
 IHC-PS – Reported in literature ¹²
 WB – Reported in literature ¹³⁻¹⁵
 Multiplex – Reported in literature ¹⁷⁻¹⁹
 Sep – Reported in literature ⁸
 Depletion – Reported in literature ²⁰

Working Dilutions

ELISA	AP conjugate	1:1,000 – 1:2,000
	HRP conjugate	1:4,000 – 1:16,000
	BIOT conjugate	1:5,000 – 1:10,000
FLISA	FITC and AF488 conjugates	1:200 – 1:400
	PE and AF647 conjugates	≤ 1 µg/mL

Other Applications Since applications vary, you should determine the optimum working dilution for the product that is appropriate for your specific need.

For Research Use Only. Not for Diagnostic or Therapeutic Use.

Handling and Storage

- The purified (UNLB) antibody is supplied as 0.5 mg of purified immunoglobulin in 1.0 mL of borate buffered saline, pH 8.2. *No preservatives or amine-containing buffer salts added.* Store at 2-8°C.
- The fluorescein (FITC) conjugate is supplied as 0.5 mg in 1.0 mL of PBS/NaN₃. Store at 2-8°C.
- The alkaline phosphatase (AP) conjugate is supplied as 1.0 mL of stock solution in 50 mM Tris/1 mM MgCl₂/50% glycerol, pH 8.0, containing NaN₃ as preservative. Store at 2-8°C or long-term at -20°C.
- The horseradish peroxidase (HRP) conjugate is supplied as 1.0 mL of stock solution in 50% glycerol/50% PBS, pH 7.4. No preservative added. Store at 2-8°C or long-term at -20°C.
- The biotin (BIOT) conjugate is supplied as 0.5 mg in 1.0 mL of PBS/NaN₃. Store at 2-8°C.
- The R-phycoerythrin (PE) conjugate is supplied as 0.1 mg in 1.0 mL of PBS/NaN₃ and a stabilizing agent. Store at 2-8°C. **Do not freeze!**
- The Alexa Fluor[®] 488 (AF488) and Alexa Fluor[®] 647 (AF647) conjugates are supplied as 0.1 mg in 0.2 mL of PBS/NaN₃. Store at 2-8°C.
- Protect fluorochrome-conjugated forms from light. Reagents are stable for the period shown on the label if stored as directed.

Warning

Some reagents contain sodium azide. Please refer to product specific (M)SDS.

References

1. Johnson S, Sypura WD, Gerding DN, Ewing SL, Janoff EN. Selective neutralization of a bacterial enterotoxin by serum immunoglobulin A in response to mucosal disease. *Infect Immun.* 1995;63:3166-73. (ELISA)
2. Opstad NL, Daley CL, Thurn JR, Rubins JB, Merrifield C, Hopewell PC, et al. Impact of Streptococcus pneumoniae bacteremia and human immunodeficiency virus type 1 on oral mucosal immunity. *J Infect Dis.* 1995;172:566-70. (ELISA)
3. Islam D, Wretling B, Ryd M, Lindberg AA, Christensson B. Immunoglobulin subclass distribution and dynamics of Shigella-specific antibody responses in serum and stool samples in shigellosis. *Infect Immun.* 1995;63:2054-61. (ELISA)
4. Camacho MT, Outschoorn I, Kováčová E, Telléz A. Distribution of immunoglobulin G (IgG) and A (IgA) subclasses following Q fever vaccination with soluble phase I Coxiella burnetii extract. *Vaccine.* 2000;18:1773-7. (ELISA)
5. Ryan ET, Bridges EA, Crean TI, Gausia K, Hamadani JD, Aziz A, et al. Local production of anti-vibrio cholerae mucosal antibody in reproductive tract tissues after cholera. *J Infect Dis.* 2001;184:643-7. (ELISA)
6. Arnold M, Zacher T, Dechant M, Kalden JR, Doxiadis II, Spriewald BM. Detection and specification of noncomplement binding anti-HLA alloantibodies. *Hum Immunol.* 2004;65:1288-96. (ELISA)
7. Fasching CE, Grossman T, Corthésy B, Plaut AG, Weiser JN, Janoff EN. Impact of the molecular form of immunoglobulin A on functional activity in defense against Streptococcus pneumoniae. *Infect Immun.* 2007;75:1801-10. (ELISA)
8. He B, Xu W, Santini PA, Polydorides AD, Chiu A, Estrella J, et al. Intestinal bacteria trigger T cell-independent immunoglobulin A₂ class switching by inducing epithelial-cell secretion of the cytokine APRIL. *Immunity.* 2007;26:812-26. (ELISA, Sep, FC, IHC-FS)
9. Geisler WM, Morrison SG, Doemland ML, Iqbal SM, Su J, Mancevski A, et al. Immunoglobulin-specific responses to Chlamydia elementary bodies in individuals with and at risk for genital chlamydial infection. *J Infect Dis.* 2012;206:1836-43. (ELISA)
10. Carson PJ, Schut RL, Simpson ML, O'Brien J, Janoff EN. Antibody class and subclass responses to pneumococcal polysaccharides following immunization of human immunodeficiency virus-infected patients. *J Infect Dis.* 1995;172:340-5. (ELISPOT)
11. Senpuku H, Asano T, Matin K, Salam MA, Tsuha Y, Horibata S, et al. Effects of human interleukin-18 and interleukin-12 treatment on human lymphocyte engraftment in NOD-scid mouse. *Immunology.* 2002;107:232-42. (IHC-FS)
12. Islam D, Veress B, Bardhan PK, Lindberg AA, Christensson B. Quantitative assessment of IgG and IgA subclass producing cells in rectal mucosa during shigellosis. *J Clin Pathol.* 1997;50:513-20. (IHC-PS)
13. Batten MR, Senior BW, Kilian M, Woof JM. Amino acid sequence requirements in the hinge of human immunoglobulin A1 (IgA1) for cleavage by streptococcal IgA1 proteases. *Infect Immun.* 2003;71:1462-9. (WB)
14. Lewis MJ, Pleass RJ, Batten MR, Atkin JD, Woof JM. Structural requirements for the interaction of human IgA with the human polymeric Ig receptor. *J Immunol.* 2005;175:6694-701. (WB)
15. Lehoux S, Mi R, Aryal RP, Wang Y, Schjoldager KT, Clausen H, et al. Identification of distinct glycoforms of IgA1 in plasma from patients with immunoglobulin A (IgA) nephropathy and healthy individuals. *Mol Cell Proteomics.* 2014;13:3097-113. (WB)
16. Avery DT, Bryant VL, Ma CS, de Waal Malefyt R, Tangye SG. IL-21-induced isotype switching to IgG and IgA by human naive B cells is differentially regulated by IL-4. *J Immunol.* 2008;181:1767-79. (FC)
17. Arnold M, Dechant M, Doxiadis II, Spriewald BM. Prevalence and specificity of immunoglobulin G and immunoglobulin A non-complement-binding anti-HLA alloantibodies in retransplant candidates. *Tissue Antigens.* 2008;72:60-6. (Multiplex)
18. Arnold M, Heinemann FM, Horn P, Ziemann M, Lachmann N, Mühlbacher A, et al. 16th IHIW: anti-HLA alloantibodies of the of IgA isotype in re-transplant candidates. *Int J Immunogenet.* 2013;40:17-20. (Multiplex)
19. Arnold M, Ntokou I, Doxiadis II, Spriewald BM, Boletis JN, Iniotaki AG. Donor-specific HLA antibodies: evaluating the risk for graft loss in renal transplant recipients with isotype switch from complement fixing IgG1/IgG3 to noncomplement fixing IgG2/IgG4 anti-HLA alloantibodies. *Transpl Int.* 2014;27:253-61. (Multiplex)
20. Kitani A, Strober W. Differential regulation of Cα1 and Cα2 germ-line and mature mRNA transcripts in human peripheral blood B cells. *J Immunol.* 1994;153:1466-77. (Depletion)

Alexa Fluor[®] 488, 647, and 555 are provided under an Intellectual property license from Life Technologies Corporation. The purchase of this product conveys to the buyer the non-transferable right to use the purchased amount of the product and components of the product in research conducted by the buyer (whether the buyer is an academic or for-profit entity). The buyer cannot sell or otherwise transfer (a) this product (b) its components or (c) materials made using this product or its components to a third party or otherwise use this product or its components or materials made using this product or its components for Commercial Purposes. Commercial Purposes means any activity by a party for consideration and may include, but is not limited to: (1) use of the product or its components in manufacturing; (2) use of the product or its components to provide a service, information, or data; (3) use of the product or its components for therapeutic, diagnostic or prophylactic purposes; or (4) resale of the product or its components, whether or not such product or its components are resold for use in research. For information on purchasing a license to this product for any other use, contact Life Technologies Corporation, 5791 Van Allen Way, Carlsbad, CA 92008 USA or outlicensing@lifetech.com.

TB9140
03-Jan-17

Corporate Offices: 160 Oxmoor Blvd • Birmingham, AL 35209 • USA Mailing Address: P.O. Box 26221 • Birmingham, AL 35260 • USA

Tel: 205.945.1774 • U.S. and Canada: 800.722.2255 • Fax: 205.945.8768

Email: info@southernbiotech.com • Website: www.southernbiotech.com